Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. - Wikidata - wikimedia - TriplyDB

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

http://www.wikidata.org/entity/Q46902397

about

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Combined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases Bioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposure Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD.Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease Salmeterol combined with fluticasone propionate improved COPD in patients during stable stage.Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls Steroid resistance in COPD? Overlap and differential anti-inflammatory effects in smokers and ex-smokers.Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in COPD.Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.Pathological networking: a new approach to understanding COPD.Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis.Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations The role of bronchodilator treatment in the prevention of exacerbations of COPD.Update in chronic obstructive pulmonary disease 2005.A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.The pharmokinetic limitations of antioxidant treatment for COPD.Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls.Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease.Inhaled therapy for stable chronic obstructive pulmonary disease.Update in chronic obstructive pulmonary disease 2006.Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.COPD: what is the unmet need?The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD

P2860

Q24197853-634A5267-3B5C-4AD9-A093-59D33E5BF7B2 Q24202510-0ED67374-03A6-4C1B-8CA0-C9CF3C257718 Q24243564-3F2700D6-0E2E-4F5F-961A-EA77E4D1BAA0 Q28083987-BCC03F97-7404-40DF-857D-A0E9E5B37A78 Q28391885-E33CEA66-06FD-4151-AB5C-BCB0B6927255 Q30355471-7DC41FE7-4CB6-49F2-A73C-A06BAF1FBA2A Q33591899-450050B9-1CB6-4F2B-8628-BBCA4D24504B Q33604883-C4414F25-F3C6-4B7A-B46A-AFF3687371ED Q33613164-0ADB5863-B5A8-4963-B413-847640DFB35B Q33689926-D0B0AEEF-0360-40BF-8E85-EC95987C6C75 Q33966009-A5CFD31B-EA2C-42CC-A01F-3D672D4EF9DF Q34036358-34E27550-C5C9-4F6B-8E6B-EBD70ECB56D7 Q34065276-4F681FDB-ED8A-4117-A012-490615F0F6AD Q34171117-AAA10798-36DD-429D-BDAF-C77E118284D6 Q34415156-7BB48C8C-21A9-4276-B4F3-439C1265C18C Q35042664-1B4ACB3A-71D9-4DFE-9D0A-A33389C2068B Q35088162-3CAAD514-5853-4638-B63F-5498F4F994AF Q35219711-ABC7EF91-FADC-413D-BCFC-C3FB86443BD5 Q35492192-9B139BB3-E863-45D8-8288-FD6EAA00AED5 Q35531955-0D720A7F-FFEF-4E52-8A61-0142FA4F8B76 Q35602749-86D27103-BBBF-49CC-A047-17366D9B70B5 Q35855187-A01F75B9-AD1B-48CC-A1E6-1B1D50247266 Q35987189-E5148BFB-876A-4893-A16F-9DDF8811D8F1 Q36169173-7EB0B7BF-DD48-443A-B74E-9BCCA7F192C0 Q36225454-DC297D1B-766D-494A-B4FE-9C345F91E1AA Q36225899-D09F1618-639F-41B6-B2E3-9A115B1A1504 Q36283909-9068DF88-4381-4499-A779-4476DF059A61 Q36302882-C541C279-6B6C-4AFD-B765-51923FEFB99A Q36389519-6A6572EA-F525-4CAF-8E10-6BBD25AF4A74 Q36438669-947DFE84-B5C7-43EB-8673-EE7083D74B58 Q36470462-D7D3757D-3AB9-44F9-8226-296FB14BE8BF Q36510045-C94E5306-7D5D-47E9-8779-19018A600D5C Q36514605-2E407861-1740-4127-BCE8-EDCAA462B3E7 Q36585746-A443BF65-6D1E-4DB0-A4FB-F62DE9AB50E6 Q36687379-43096C6F-23EE-4A08-864C-06A35C531A3C Q36787296-8571384C-A221-46F2-A559-E690ED4333AC Q36838782-64307A8F-BD1A-4C1B-872F-5D907997BBD0 Q36956720-7E4040B6-A1F4-4ECA-A95B-60F469D6A9EB Q36964961-8D2B79B6-C61D-41B7-8CA4-9DF68E7E9769 Q37017315-84708570-2DF7-4E23-A585-C6FBED428A64

P2860

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.

http://www.wikidata.org/entity/Q46902397

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@en

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@nl

type

label

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@en

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@nl

prefLabel

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@en

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@nl

P1433

Q46902397-DE23B482-DD47-4A1A-8A8A-A712700E26D3

P1476

Q46902397-EB72C7B3-3959-421D-BC8D-9AB77A7C7A65

P2093

Q46902397-0BD993A1-EE85-43DE-B881-A364B7E5A718

Q46902397-1B6DF0AB-8148-482B-897B-0672B1C46AAA

Q46902397-4770A9F8-F626-407B-A88F-B6F1A20F1241

Q46902397-48097FD5-124B-4284-BC42-648507554FD7

Q46902397-48AEB637-C893-4C04-BEAD-7F631734F4A3

Q46902397-7A106F0F-83D4-4EA2-98C5-C02D8F514B76

Q46902397-9FE7D17D-19D4-4313-8F6C-607C75F2FAC4

Q46902397-F7AE38B8-F2DE-4268-92FC-30F442E7A982

P2860

Q46902397-1923FDA2-ABF7-455D-83E3-1AECCCD26F3E

Q46902397-1E5A17F8-F697-4126-8A48-3EF588D82958

Q46902397-2241906A-A0E7-4B37-8A33-B71CAEE3EB8B

Q46902397-2D393D0B-0065-4611-9FA8-C5F2D05BDEEC

Q46902397-32F6423B-44E4-4647-A008-40F29F39B9A3

Q46902397-3457A375-9DE3-4337-9A50-3CC3313FDBF0

Q46902397-361E6FF7-F095-4E7F-BD0D-A1B138D6E909

Q46902397-362CE235-0932-4600-8770-B58C32962FEC

Q46902397-3C4C5166-19A9-49D0-A0CD-6A154F723423

Q46902397-409CFD50-552E-4442-B986-CBD0A850464B

P304

Q46902397-AC2D7B37-4821-4E12-A8A1-1994B4CC3195

P31

Q46902397-24FFE0FC-B712-44FB-9CFF-521972A86EEA

P356

Q46902397-CF531C52-EBFA-4B9C-8DEC-01B9944ABCD8

P407

Q46902397-57136DE2-9B3F-44A3-A86D-C7AC06C83FB6

P433

Q46902397-A749CC26-8E8E-4523-B6C7-FAD68B8FBFC7

P478

Q46902397-5D68DB5B-3A8A-4152-B87E-F1817E826D40

P50

Q46902397-64587295-C142-49B5-9FFA-C82BAC7DB9A5

Q46902397-95568E52-F5BB-41F0-8908-748A4685041F

P577

Q46902397-20374D29-9090-4246-80A2-DCF11B10088B

P698

Q46902397-E767D5AA-06F1-426A-B0E8-2FEFDCFCFFE1

P356

RCCM.200508-1321OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Antiinflammatory effects of sa ...... onic obstructive lung disease.

@en

P2093

Debbie Parker

http://www.w3.org/2001/XMLSchema#string

Jie Zhu

http://www.w3.org/2001/XMLSchema#string

Malcolm Johnson

http://www.w3.org/2001/XMLSchema#string

Neil C Barnes

http://www.w3.org/2001/XMLSchema#string

Peter A Davis

http://www.w3.org/2001/XMLSchema#string

Peter K Jeffery

http://www.w3.org/2001/XMLSchema#string

SCO30005 Study Group

http://www.w3.org/2001/XMLSchema#string

Yu-Sheng Qiu

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

The nature of small-airway obstruction in chronic obstructive pulmonary disease

Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition.

Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

Neutrophils and the pathogenesis of COPD.

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

Ongoing airway inflammation in patients with COPD who do not currently smoke

Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue.

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

P304

736-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200508-1321OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

173

http://www.w3.org/2001/XMLSchema#string

P50

Neil C. Thomson

P577

2006-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16424444

http://www.w3.org/2001/XMLSchema#string